Content area

|
|

Hæmning af proteinet PCSK9 er en lovende behandling af hyperkolesterolæmi og forebyggelse af hjerte-kar-sygdom

Forfatter(e)
Morten Krogh Christiansen & Henrik Kjærulf Jensen Afdeling for Hjerte-sygdomme, Aarhus Universitetshospital Ugeskr Læger 2015;177:V11140582
Reference: 
Ugeskr Læger 2015;177:V11140582
Blad nummer: 
Sidetal: 
2-5
Inhibition of the protein PCSK9 is a promising target in the prevention of cardiovascular disease
Recent research in genetics has revealed that PCSK9 – which codes for proprotein convertase subtilisin/kexin type 9 (PCSK9) – plays a major role in cholesterol regulatory pathways. Normal genetic variations in PCSK9 have a great impact on low-density lipoprotein cholesterol levels and hence the risk of cardio-vascular disease. This has led to huge efforts in inhibiting PCSK9. Recent clinical phase II trials with monoclonal antibodies against PCSK9 have shown great results for lowering low-density lipoprotein cholesterol levels making the inhibition of PCSK9 a promising target in the prevention of cardiovascular disease.
Du skal være logget ind for at læse denne artikel
Log ind

Right side

af Per Kjærsgaard | 19/01
1 Kommentar
af Peter Søndergaard | 18/01
3 kommentarer
af Mads Henrik Koch Hansen | 16/01
2 kommentarer
af Lars Guttorm | 14/01
5 kommentarer
af Morten Ellemose Gulev | 14/01
4 kommentarer
af Henning Damgaard Laugesen | 14/01
1 Kommentar
af Jette E. Hansen Kristiansen | 14/01
1 Kommentar
af Eva Pernille Due | 13/01
6 kommentarer